Theravance Biopharma (TBPH) Net Cash Flow (2014 - 2026)

Theravance Biopharma (TBPH) has reported Net Cash Flow for 13 consecutive years, with $120.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 65.2% year-over-year to $120.3 million; the TTM figure through Mar 2026 stood at $177.5 million (up 212.59% YoY), while the FY2025 annual figure was $130.0 million, up 7537.59% from the prior year.
• Net Cash Flow improved to $120.3 million in Q1 2026 per TBPH's latest filing, from -$7.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $171.3 million in Q2 2025 and bottomed at -$758.3 million in Q3 2022.
• Historically, Net Cash Flow has averaged -$40.7 million across 5 years, with a median of -$7.1 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow sank 2607.53% — and 2025, when it jumped 2387.22%.
• Theravance Biopharma's Net Cash Flow stood at $78.8 million in 2022, then slumped by 140.79% to -$32.1 million in 2023, then jumped by 144.86% to $14.4 million in 2024, then tumbled by 148.32% to -$7.0 million in 2025, then surged by 1826.64% to $120.3 million in 2026.
• Business Quant data shows TBPH's Net Cash Flow at $120.3 million in Q1 2026, -$7.0 million in Q4 2025, and -$107.2 million in Q3 2025.